In September 2019, the Company raised net proceeds of approximately $271.5 million from the sale of 7,187,500 shares of its common stock in a follow-on public offering, including 937,500 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.

In November 2018, the Company raised net proceeds of approximately $298.5 million from the sale of 18,602,941 shares of its common stock in a follow-on public offering, including 2,426,470 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.

In August 2016, the Company raised net proceeds of approximately $215.9 million from the sale of 6,969,696 shares of its common stock in a follow-on public offering, including 909,090 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.

In January 2016, the Company raised net proceeds of approximately $281.6 million from the sale of 10,344,827 shares of its common stock in a follow-on public offering. In connection with the January 2016 offering, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with 667, L.P., Baker Brothers Life Sciences, L.P. and 14159, L.P. (the “Baker Entities”), all of which are existing stockholders of the Company and are affiliated with two of its directors, Julian C. Baker and Dr. Stephen R. Biggar. Under the Registration Rights Agreement, the Company agreed that, if the Baker Entities demand that the Company register their shares of its common stock, par value $0.0001 per share, for resale under the Securities Act of 1933, as amended (the “Securities Act”), the Company would be obligated to effect such registration. The Company’s registration obligations under the Registration Rights Agreement cover all shares of its common stock now held or later acquired by the Baker Entities (including approximately $75.0 million, $43.0 million, $200.0 million, and $62.5 million of shares that the Baker Entities purchased at the public offering price in the January 2016, August 2016, November 2018, and September 2019 offerings, respectively), will continue in effect for up to 10 years, and include the Company’s obligation to facilitate certain underwritten public offerings of its common stock by the Baker Entities in the future. The Company has agreed to bear all expenses incurred by it in effecting any registration pursuant to the Registration Rights Agreement as well as the legal expenses of the Baker Entities of up to $50,000 per underwritten public offering effected pursuant to the Registration Rights Agreement. On May 3, 2019, pursuant to the Registration Rights Agreement, the Company filed a registration statement covering all shares owned by the Baker Entities as of April 29, 2019.

In December 2012, the Company raised net proceeds of $80.5 million through the sale of 19,000,000 shares of its common stock at a price of $4.43 per share and the sale of warrants to purchase 500,000 shares of its common stock at a price of $4.42 per warrant share in a private equity financing. The warrants have an exercise price of $0.01 per share. In accordance with authoritative accounting guidance, the warrants’ value of $2.2 million was determined on the date of grant using the Black-Scholes model and recorded as a component of stockholders’ equity within additional paid-in capital. Per their terms, the warrants to purchase 500,000 shares of common stock, of which 493,145 remained outstanding at December 31, 2019, may not be exercised if the holder’s ownership of the Company’s common stock would exceed 19.99 percent following such exercise.

The Company’s 2010 Equity Incentive Plan, as amended to date (the “2010 Plan”), permits the grant of options to employees, directors and consultants. In addition, the 2010 Plan permits the grant of stock bonuses, rights to purchase restricted stock, and other stock awards. The exercise price of options granted under the 2010 Plan cannot be less than 100 percent of the fair market value of the common stock on the date of grant and the maximum term of any option is 10 years. Options granted under the 2010 Plan generally vest over a four-year period. All shares that remained eligible for grant under the Company’s 2004 Equity Incentive Plan (the “2004 Plan”) at the time of approval of the 2010 Plan were transferred to the 2010 Plan. The 2010 Plan share reserve also has been, and may be, increased by the number of shares that otherwise would have reverted to the 2004 Plan reserve after June 2010. In June 2015, June 2016, June 2017, June 2018, and June 2019, the Company’s stockholders approved amendments to its 2010 Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 5,000,000 shares, 3,000,000 shares, 5,500,000 shares, 6,700,000 shares, and 8,300,000 shares, respectively. In June 2019, the Company’s stockholders also approved amendment to its 2004 Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 600,000 shares. At December 31, 2019, there were 31,254,090 shares of common stock authorized for issuance, of which 12,381,699 shares were available for new grants under the 2010 Plan.

The 2004 Plan provided for the grant of options to employees, directors and consultants. The exercise price of options granted under the 2004 Plan was at 100 percent of the fair market value of the common stock on the date of grant and the maximum term of any option was 10 years. Options granted under the 2004 Plan generally vested over a four-year period.

The following table summarizes the Company’s stock option activity during the year ended December 31, 2019:

	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2018		19,868,781		$	28.04
Granted		3,502,129		$	28.22
Exercised		(3,880,757	)	$	24.73
Cancelled/forfeited		(2,062,925	)	$	29.10
Outstanding at December 31, 2019		17,427,228		$	28.69		7.5	$	247,336
Vested at December 31, 2019		8,622,679		$	30.18		6.5	$	109,605
Unvested at December 31, 2019		8,804,549		$	27.23		8.5	$	137,731
Exercisable at December 31, 2019		8,622,679		$	30.18		6.5	$	109,605

The aggregate intrinsic value of options exercisable as of December 31, 2019 is calculated as the difference between the exercise price of the underlying options and the closing market price of the Company’s common stock on that date, which was $42.78 per share. The aggregate intrinsic value of options exercised during the years ended December 31, 2019, 2018, and 2017 was approximately $56.6 million, $11.2 million, and $24.4 million, respectively, determined as of the date of exercise. The Company received $96.0 million in cash from options exercised during the year ended December 31, 2019.

The weighted average per share fair value of options granted during the years ended December 31, 2019, 2018, and 2017 was approximately $15.97, $12.14, and $21.11, respectively. As of December 31, 2019, total unrecognized compensation cost related to stock options was approximately $119.3 million, and the weighted average period over which this cost is expected to be recognized is approximately 2.8 years.

In 2018, the Company began granting RSUs pursuant to the 2010 Plan and satisfies such grants through the issuance of new shares. RSUs are share awards that, upon vesting, will deliver to the holder shares of the Company’s common stock. RSUs generally vest over a four-year period with equal vesting on anniversaries of the grant date.

The following table summarizes the Company’s RSU activity during the year ended December 31, 2019:

	Number of Shares			Weighted Average Grant Date Fair Value		Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2018		373,706		$	21.07
Granted		1,287,453		$	25.22
Vested		(84,409	)	$	21.05
Cancelled/forfeited		(131,587	)	$	23.97
Outstanding at December 31, 2019		1,445,163		$	24.50	$	61,824

The weighted average per share fair value of RSUs granted during the years ended December 31, 2018 was approximately $21.07. As of December 31, 2019, total unrecognized compensation cost related to restricted stock options was approximately $22.7 million, and the weighted average period over which this cost is expected to be recognized is approximately 3.8 years.

The Company’s 2004 Employee Stock Purchase Plan (the “Purchase Plan”) became effective upon the closing of the Company’s initial public offering in June 2004. The Purchase Plan included an “evergreen” provision providing that a limited number of additional shares may be added to the shares authorized for issuance on the date of each annual meeting of stockholders for a period of 10 years, which ended with the meeting in 2014. In June 2016, the Company’s stockholders approved an amendment to the Purchase Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 400,000 shares, and at December 31, 2019, a total of 2,525,000 shares of common stock had been reserved for issuance under the Purchase Plan. At December 31, 2019, 485,254 shares of common stock remained available for issuance pursuant to the Purchase Plan. Eligible employees who elect to participate in an offering under the Purchase Plan may have up to 15 percent of their earnings withheld, subject to certain limitations, to purchase shares of common stock pursuant to the Purchase Plan. The price of common stock purchased under the Purchase Plan is equal to 85 percent of the lower of the fair market value of the common stock at the commencement date of each offering period or the relevant purchase date. During the years ended December 31, 2019, 2018, and 2017, a total of 269,037, 233,720, and 192,402 shares of common stock were issued under the Purchase Plan at average per share prices of $16.41, $15.75, and $23.50, respectively. The weighted average per share fair value of purchase rights granted during the years ended December 31, 2019, 2018, and 2017 was $14.24, $8.25, and $11.44, respectively. During the years ended December 31, 2019, 2018, and 2017, the Company recorded cash received from the exercise of purchase rights of $4.4 million, $3.7 million, and $4.5 million, respectively.